- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375253
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
A Phase I Trial of Donor Enriched Activated NK (DEA-NK) Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with relapse refractory myeloid malignancies [acute myeloid leukemia (AML) myelodysplastic (MDS)/myeloproliferative (MPD) disorders] have no therapeutic options for long term remission. Haploidentical cytokine activated natural killer (NK) cell immunotherapy has been used with some success in treating patients with refractory relapsed AML. One limiting factor to the in-vivo expansion of infused activated NK cells is the recovery of recipient's immune system rejecting the infused NK cells. The use of haploidentical activated NK cell therapy post haploidentical transplant is an attractive option to induce in-vivo persistence of the infused NK cells and support anti leukemic efficacy.
This is a pilot trial testing the feasibility, safety and immunologic effects of dose escalated donor enriched activated natural killer cell infusion (DEA-NK) on day +7 post haploidentical stem cell transplantation. Participants must be adult patients with relapse refractory AML, MDS, or MPD, available haploidentical related donor, and adequate organ functions to undergo stem cell transplant. Participants will be followed for 6 months and 1 year following transplant.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to understand and sign informed Consent
- Age > 19 years and ≤ 70 years.
- Deemed eligible for allogeneic stem cell transplantation with a minimum KPS of 70% (Appendix A).
- Available HLA-haploidentical related donor as defined in section 5.2.1
Subjects with adequate organ functions as measured by:
- Cardiac: Left ventricular ejection fraction at rest must be >45%,
- Hepatic: Bilirubin < 2.5 mg/dL except for Gilbert syndrome; and ALT, AST, and Alkaline Phosphatase < 5 x ULN.
- Renal: GFR > 50 mL/min/1.73m2,
- Pulmonary: FEV 1, FVC, DLCO ion capacity) > 45% predicted (corrected for hemoglobin); or 02 saturation > 92% on room air.
- Able to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on Day -3
- Subjects with prior central nervous system (CNS) involvement are eligible provided that it has been treated and cerebral spinal fluid (CSF) is clear for at least 2 weeks prior to enrollment. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.
- Clinical diagnosis of one of the following:
A. Refractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one or more cycles of re-induction therapy. decitabine or azacytidine with venetoclax will be considered as one cycle of induction therapy.
B. Myelodysplastic Syndrome+/- myeloproliferative neoplasm MDS/MPN which failed to adequately respond (persistence of blasts >5%) to hypomethylating agents and or chemotherapy (minimum of 3 cycles of hypomethylating agents or 2 cycles of hypomethylating + venetoclax or one cycle of induction chemotherapy)
Exclusion Criteria:
- Autologous hematopoietic stem cell transplant < 3 months prior to enrollment.
- Circulating peripheral blood blast count > 1000/µl (despite hydroxyurea and or leukapheresis).
- Previous allogeneic stem cell transplant.
- Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of ≥5000 as assessed by the single antigen bead assay, < 6 weeks prior to starting transplant conditioning
- Uncontrolled angina, severe uncontrolled ventricular arrhythmias.
- Received any investigational drugs within the 14 days prior to the first day of transplant conditioning (starting on day -6)
Women of child-bearing potential must not be pregnant and/or breastfeeding
a. Note: All females with intact ovaries and uterus will have two pregnancy tests as part of standard of care pre-transplant protocols.
- Evidence of HIV infection or known HIV positive serology (completed as part of pre-transplant testing).
- Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).
- Non-hematologic malignancy within prior three (3) years, with the exception of squamous cell or basal cell skin carcinoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Donor Enriched Activated NK Infusion (DEA-NK)
Infusion of DEA-NK on day +7 post-transplant
|
αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of successful DEA-NK cell infusions
Time Frame: 100 Days
|
Assess the feasibility of infusing activated enriched donor natural killer cell infusion (DEA-NK) at day +7 post-transplant by the ability to manufacture and administer the DEA-NK cells at study dose levels.
|
100 Days
|
Number of adverse events for those who have a DEA-NK cell infusion
Time Frame: 100 Days
|
Assess safety of the DEA-NK cell infusions by recording adverse events experienced by subjects at each dose level.
|
100 Days
|
Maximum tolerated dose of DEA-NK cell infusions
Time Frame: 100 Days
|
To determine the maximum tolerated dose (MTD) of DEA-NK cell infusion as determined by dose limiting toxicities (DLT) observed.
|
100 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-Relapse Mortality Rate
Time Frame: 1 year
|
Non-Relapse Mortality (NRM) at 100 days, 180 days and 1 year
|
1 year
|
Time to neutrophil recovery
Time Frame: 21 Days
|
Time to neutrophil recovery defined as the first of 3 consecutive days following the nadir that the absolute neutrophil count is at least 500/µl
|
21 Days
|
Time to platelet recovery
Time Frame: 21 Days
|
Time to platelet recovery defined as the first day that the platelet count is at least 20,000/µl without a transfusion in the preceding 7 days
|
21 Days
|
Incidence of graft failure
Time Frame: 35 Days
|
Incidence of graft failure as defined by ANC < 500/µl by Day +35 in the absence of disease recurrence
|
35 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zaid Al-Kadhimi, MD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0158-22-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on Donor Enriched Activated Natural Killer Cell Infusion
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedAcute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsKorea, Republic of
-
Michael Pulsipher, MDSeattle Children's Hospital; Nationwide Children's HospitalEnrolling by invitation
-
National Cancer Institute (NCI)Completed
-
Southwest Hospital, ChinaUnknownHepatocellular CarcinomaChina
-
Wenxiang WangShanghai Houchao Biotechnology Co., LtdUnknownNon-small Cell Lung CancerChina
-
Hospital de Clinicas de Porto AlegreUnknown
-
Hospital Universitario La PazCompletedRelapsed/Refractory Paediatric Acute LeukaemiaSpain
-
Minghui ZhangShanghai Public Health Clinical Center; First Hospital of Tsinghua UniversityRecruitingHepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-small Cell Lung CancerChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting